Audentes Therapeutics (BOLD): Initiating Coverage with an Outperform Rating - Piper Jaffray

August 15, 2016 7:31 AM EDT
Get Alerts BOLD Hot Sheet
Price: $17.42 --0%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade BOLD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray analyst, Joshua Schimmer, initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Overweight rating price target of $24.

The company is capitalizing on recent wins in the gene therapy field and is
charting its own path with a differentiated strategy, focusing on orphan and ultra-orphan
diseases with a high unmet need which is uniquely suited to gene therapy. BOLD's lead
program targets X-linked myotubular myopathy (XLMTM), with robust preclinical data
indicating long-term durable correction of the phenotype with clinical data next year.
Behind XLMTM, the company has attractive programs with promising preclinical data
for Crigler-Najjar, Pompe, and Catecholaminergic polymorphic ventricular tachycardia
(CPVT). As such, we see BOLD as well-positioned in the rapidly evolving gene therapy

The $24 PT is based on a based on a DCF analysis through 2024E.

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $14.70 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot List

Related Entities

Piper Jaffray, Joshua Schimmer

Add Your Comment